Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent MDT Stock Price: $78.37
Summary: Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
Richard Newitter analyst at Truist Financial reiterates coverage on Medtronic (MDT) stock in the energy sector with a Hold rating and has set MDT's stock price target at $84.
TipRanks.com reports that Medtronic currently has 5 analysts offering 12-month price targets on MDT and the consensus is a Moderate Buy rating with an average stock price target of $84.20. The most recent MDT stock price we have is $78.37 and we are not making any MDT forecasts at this time.
In addition, TradingView issued a Buy rating for MDT over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on MDT. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MDT, please click here >>
Agilent, A
Recent A Stock Price: $123.99
Summary: Agilent Technologies, Inc. is an original equipment manufacturer of a broad-based portfolio of test and measurement products serving multiple end markets. Recently, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG).The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers' representatives, telesales and electronic commerce, as necessary.
Timothy Daley analyst at Wells Fargo reiterates coverage on Agilent (A) stock in the energy sector with a Buy rating and has set A's stock price target at $145.
TipRanks.com reports that Agilent currently has 5 analysts offering 12-month price targets on A and the consensus is a Moderate Buy rating with an average stock price target of $128.00. The most recent A stock price we have is $123.99 and we are not making any A forecasts at this time.
In addition, TradingView issued a Buy rating for A over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on A. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on A, please click here >>
Enanta Pharmaceuticals, ENTA
Recent ENTA Stock Price: $8.99
Summary: Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Jay Olson analyst at Oppenheimer reiterates coverage on Enanta Pharmaceuticals (ENTA) stock in the energy sector with a Hold rating and has set ENTA's stock price target at $21.
TipRanks.com reports that Enanta Pharmaceuticals currently has 5 analysts offering 12-month price targets on ENTA and the consensus is a Moderate Buy rating with an average stock price target of $25.20. The most recent ENTA stock price we have is $8.99 and we are not making any ENTA forecasts at this time.
In addition, TradingView issued a sell rating for ENTA over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ENTA. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ENTA, please click here >>
Mediwound, MDWD
Recent MDWD Stock Price: $8.70
Summary: MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel.
Swayampakula Ramakanth analyst at H.C. Wainwright reiterates coverage on Mediwound (MDWD) stock in the energy sector with a Buy rating and has set MDWD's stock price target at $26.
TipRanks.com reports that Mediwound currently has 4 analysts offering 12-month price targets on MDWD and the consensus is a Strong Buy rating with an average stock price target of $28.00. The most recent MDWD stock price we have is $8.70 and we are not making any MDWD forecasts at this time.
In addition, TradingView issued a Buy rating for MDWD over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MDWD. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MDWD, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
==============================================================================
